# Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

> **NCT03301467** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 57 (actual)

## Conditions studied

- C3 Glomerulopathy (C3G)

## Interventions

- **DRUG:** Avacopan
- **DRUG:** Avacopan Matching Placebo

## Key facts

- **NCT ID:** NCT03301467
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-29
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-10-27
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301467, "Controlled Trial Evaluating Avacopan in C3 Glomerulopathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03301467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*